bpc-157 utilisation Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions BPC-157 Archives - Free Medical
Description
The risk appears low and was not dose-dependent
Oral BPC-157 is often discussed for gastrointestinal concerns because it passes through the digestive tract and appears relatively stable in acidic environments
PubMed Goldstein, A.L., Hannappel, E., Sosne, G., & Kleinman, H.K
Sep-Oct 2012;29(5):599-615
Schedule: Subcutaneous injections 5 days per week (or 3/week) for 812 weeks, optionally extended to ~16 weeks
This product is sold strictly for in-vitro laboratory research purposes
